Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis
Sign Up to like & getrecommendations! Published in 2018 at "Respiration"
DOI: 10.1159/000486286
Abstract: Background: Cardiovascular comorbidities are frequent in patients with idiopathic pulmonary fibrosis (IPF), and many patients with IPF receive treatment with statins to reduce cardiovascular risk. Objectives: We investigated whether statin use at baseline was associated… read more here.
Keywords: idiopathic pulmonary; statin; effect nintedanib; pulmonary fibrosis ... See more keywords
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Respiratory and Critical Care Medicine"
DOI: 10.1164/rccm.201602-0402oc
Abstract: Rationale: In the absence of a surgical lung biopsy, patients diagnosed with idiopathic pulmonary fibrosis (IPF) in clinical practice could participate in the INPULSIS trials of nintedanib if they had honeycombing and/or traction bronchiectasis plus… read more here.
Keywords: biopsy; idiopathic pulmonary; pulmonary fibrosis; effect nintedanib ... See more keywords
Effect of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of respiratory and critical care medicine"
DOI: 10.1164/rccm.201610-2033le
Abstract: for the patients in the EBV group compared with –148 (SD, 862) in the control group (10). Although the relatively small sample size and short follow-up of 6 months are limitations of this study, the… read more here.
Keywords: nintedanib patients; idiopathic pulmonary; group; pulmonary fibrosis ... See more keywords
Effect of nintedanib on composite physiologic index (CPI) in idiopathic pulmonary fibrosis (IPF)
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.oa3403
Abstract: Background: In the Phase III INPULSIS ® trials, nintedanib 150 mg twice daily slowed disease progression in patients with IPF by significantly reducing the annual rate of decline in FVC. Patients with FVC ≥50% predicted,… read more here.
Keywords: week; cpi; effect; effect nintedanib ... See more keywords